Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
A 17-alkylated orally active androgenic steroid. A Schedule IV drug in Canada.
- Mechanism
- Curator reviewed
The effects of calusterone in humans most likely occur by way of two main mechanisms: by activation of the androgen receptor, and by conversion to estradiol and activation of certain estrogen receptors. Using testosterone as the prime example, free testosterone (T) is transported into the cytoplasm of target tissue cells, where it can bind to the androgen receptor, or can be reduced to 5α-dihydrotestosterone (DHT) by the cytoplasmic enzyme 5α-reductase. DHT binds to the same androgen receptor even more strongly than T, so that its androgenic potency is about 2.5 times that of T. The T-receptor or DHT-receptor complex undergoes a structural change that allows it to move into the cell nucleus and bind directly to specific nucleotide sequences of the chromosomal DNA. The areas of binding are called hormone response elements (HREs), and influence transcriptional activity of certain genes, producing the androgen effects.
- Primary indication
- An anabolic steroid which can theoretically aid in restauration and buildup of certain tissues, especially muscle.Curator reviewed
- Formula / weight
- C21H32O2 · 316.4776 g/mol (avg)
- Code names
- NSC-88536 · U-22,550 · U-22550i
Resolves to
IVFYLRMMHVYGJH-PVPPCFLZSA-NSMILES[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@H](C)CC2=CC(=O)CC[C@]12CWhat you can answer from here — as of September 20, 2026
Which drugs share a target with Calusterone, and which of those have an active Phase 3 trial?